KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach

Por de Castro Carpeño, Javier, Belda-Iniesta, Cristóbal
Publicado no Transl Lung Cancer Res (2013)

Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe

Por Walleser, Silke, Ray, Joshua, Bischoff, Helge, Vergnenègre, Alain, Rosery, Hubertus, Chouaid, Christos, Heigener, David, de Castro Carpeño, Javier, Tiseo, Marcello, Walzer, Stefan
Publicado em 2012

Biomarkers of erlotinib response in non-small cell lung cancer tumors that do not harbor the more common epidermal growth factor receptor mutations

Por López-Ayllón, Blanca D, de Castro-Carpeño, Javier, Rodriguez, Carlos, Pernía, Olga, de Cáceres, Inmaculada Ibañez, Belda-Iniesta, Cristobal, Perona, Rosario, Sastre, Leandro
Publicado no Int J Clin Exp Pathol (2015)

Prognostic factors for survival in patients with metastatic lung adenocarcinoma: An analysis of the SEER database

Por Campos‐Balea, Begoña, de Castro Carpeño, Javier, Massutí, Bartomeu, Vicente‐Baz, David, Pérez Parente, Diego, Ruiz‐Gracia, Pedro, Crama, Leonardo, Cobo Dols, Manuel
Publicado no Thorac Cancer (2020)

Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug–drug interaction study in patients with ALK + advanced tumors...

Por Hurtado, Felipe K., de Braud, Filippo, De Castro Carpeño, Javier, de Miguel Luken, Maria Jose, Wang, Ding, Scott, Jeffrey, Lau, Yvonne Y., McCulloch, Tracey, Mau-Sorensen, Morten
Publicado no Cancer Chemother Pharmacol (2021)

KRAS Mutations in Primary Colorectal Cancer Tumors and Related Metastases: A Potential Role in Prediction of Lung Metastasis

Por Cejas, Paloma, López-Gómez, Miriam, Aguayo, Cristina, Madero, Rosario, de Castro Carpeño, Javier, Belda-Iniesta, Cristóbal, Barriuso, Jorge, Moreno García, Víctor, Larrauri, Javier, López, Rocío, Casado, Enrique, Gonzalez-Barón, Manuel, Feliu, Jaime
Publicado em 2009

Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non–Small Cell Lung Cancer: The AvaALL Randomized Clinical T...

Por Gridelli, Cesare, de Castro Carpeno, Javier, Dingemans, Anne-Marie C., Griesinger, Frank, Grossi, Francesco, Langer, Corey, Ohe, Yuichiro, Syrigos, Konstantinos, Thatcher, Nick, Das-Gupta, Ashis, Truman, Matt, Donica, Margarita, Smoljanovic, Vlatka, Bennouna, Jaafar
Publicado no JAMA Oncol (2018)

A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas

Por Lin, Chia-Chi, Arkenau, Hendrik-Tobias, Lu, Sharon, Sachdev, Jasgit, de Castro Carpeño, Javier, Mita, Monica, Dziadziuszko, Rafal, Su, Wu-Chou, Bobilev, Dmitri, Hughes, Lorraine, Chan, Jian, Zhang, Zhi-Yi, Weiss, Glen J.
Publicado no Br J Cancer (2019)

Epidemiology and characteristics of febrile neutropenia in oncology patients from Spanish tertiary care hospitals: PINNACLE study

Por DE CASTRO CARPEÑO, JAVIER, GASCÓN-VILAPLANA, PERE, TEJERINA, ANA MARIA CASAS-FERNÁNDEZ-DE, ANTÓN-TORRES, ANTONIO, LÓPEZ-LÓPEZ, RAFAEL, BARNADAS-MOLINS, AGUSTÍ, CRUZ-HERNÁNDEZ, JUAN JESÚS, MASSUTI-SUREDA, BARTOMEU, CAMPS-HERRERO, CARLOS, ARANDA-AGUILAR, ENRIQUE, LASERNA, FRANCISCO JOSÉ REBOLLO
Publicado no Mol Clin Oncol (2015)

The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib

Por Vishwanathan, Karthick, Dickinson, Paul A., So, Karen, Thomas, Karen, Chen, Yuh‐Min, De Castro Carpeño, Javier, Dingemans, Anne‐Marie C., Kim, Hye Ryun, Kim, Joo‐Hang, Krebs, Matthew G., Chih‐Hsin Yang, James, Bui, Khanh, Weilert, Doris, Harvey, R. Donald
Publicado no Br J Clin Pharmacol (2018)

Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)

Por Liu, Stephen V., Reck, Martin, Mansfield, Aaron S., Mok, Tony, Scherpereel, Arnaud, Reinmuth, Niels, Garassino, Marina Chiara, De Castro Carpeno, Javier, Califano, Raffaele, Nishio, Makoto, Orlandi, Francisco, Alatorre-Alexander, Jorge, Leal, Ticiana, Cheng, Ying, Lee, Jong-Seok, Lam, Sivuonthanh, McCleland, Mark, Deng, Yu, Phan, See, Horn, Leora
Publicado no J Clin Oncol (2021)

Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis

Por Antonia, Scott J, Borghaei, Hossein, Ramalingam, Suresh S, Horn, Leora, De Castro Carpeño, Javier, Pluzanski, Adam, Burgio, Marco A, Garassino, Marina, Chow, Laura Q M, Gettinger, Scott, Crinò, Lucio, Planchard, David, Butts, Charles, Drilon, Alexander, Wojcik-Tomaszewska, Joanna, Otterson, Gregory A, Agrawal, Shruti, Li, Ang, Penrod, John R, Brahmer, Julie
Publicado no Lancet Oncol (2019)

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer

Por Borghaei, Hossein, Gettinger, Scott, Vokes, Everett E., Chow, Laura Q. M., Burgio, Marco Angelo, de Castro Carpeno, Javier, Pluzanski, Adam, Arrieta, Oscar, Frontera, Osvaldo Arén, Chiari, Rita, Butts, Charles, Wójcik-Tomaszewska, Joanna, Coudert, Bruno, Garassino, Marina Chiara, Ready, Neal, Felip, Enriqueta, García, Miriam Alonso, Waterhouse, David, Domine, Manuel, Barlesi, Fabrice, Antonia, Scott, Wohlleber, Markus, Gerber, David E., Czyzewicz, Grzegorz, Spigel, David R., Crino, Lucio, Eberhardt, Wilfried Enst Erich, Li, Ang, Marimuthu, Sathiya, Brahmer, Julie
Publicado no J Clin Oncol (2021)